Actively Recruiting
Herombopag for Chemotherapy-induced Thrombocytopenia
Led by Institute of Hematology & Blood Diseases Hospital, China · Updated on 2025-02-24
50
Participants Needed
1
Research Sites
198 weeks
Total Duration
On this page
Sponsors
I
Institute of Hematology & Blood Diseases Hospital, China
Lead Sponsor
T
Tianjin Medical University Cancer Institute and Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
To evaluate the efficacy and safety of Herombopag to treat chemotherapy-induced thrombocytopenia in Solid Tumors
CONDITIONS
Official Title
Herombopag for Chemotherapy-induced Thrombocytopenia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older, male or female
- Diagnosed with chemotherapy-induced thrombocytopenia
- Ineffective response after repeated treatment with recombinant human thrombopoietin or interleukin 11
- Stopped radiotherapy or chemotherapy for more than 1 month
- Platelet count below 30 x 10^9/L with bleeding tendency
- Estimated survival period of at least 6 months
- Willing to voluntarily sign informed consent and follow the study plan
- Liver and kidney function less than 1.5 times the upper limit of normal
- Practicing acceptable contraception; women of childbearing potential must have a negative serum pregnancy test during the study
You will not qualify if you...
- Uncontrollable primary diseases of important organs, including extensive malignant tumor metastasis, liver failure, heart failure, or kidney failure
- Poor compliance
- Positive tests for HIV, hepatitis B, hepatitis C, hepatitis D, syphilis, Epstein-Barr virus DNA, or cytomegalovirus DNA
- Extensive and severe bleeding such as hemoptysis, upper gastrointestinal bleeding, or intracranial hemorrhage
- Current heart disease requiring treatment or poorly controlled hypertension
- Thrombotic diseases including pulmonary embolism, thrombosis, or atherosclerosis
- History of allogeneic stem cell or organ transplantation
- Mental disorders preventing informed consent or trial participation
- Persistent toxic symptoms from previous treatments
- Other serious diseases restricting participation such as diabetes, severe heart failure, myocardial obstruction, unstable arrhythmia, unstable angina, gastric ulcers, or autoimmune diseases
- Sepsis or irregular bleeding
- Concurrent use of antiplatelet drugs
- Pregnant, suspected pregnancy, or breastfeeding
- Pre-existing cardiac disease including severe heart failure (NYHA Grade III/IV), arrhythmia requiring treatment, or recent myocardial infarction
- Patients with arrhythmias known to increase thrombotic risk or prolonged QT intervals
- Investigator judgment that participation is not appropriate due to other conditions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese Academy of Medical Science and Blood Disease Hospital
Tianjin, Tianjin Municipality, China, 300020
Actively Recruiting
Research Team
Y
Yunfei Chen, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here